Maintain Connections (#tiptuesday)! Studies have shown that increased social activity is linked to a lower rate of cognitive decline [1]. To stay social, connect with friends and family, or consider volunteering for a local organization. #modifiableriskfactor #prevention #healthandwellness #lifestyle #brainhealth #cognitivescreening #Cognivue Reference: 1. James BD, Wilson RS, Barnes LL, Bennett DA. Late-life social activity and cognitive decline in old age. J Int Neuropsychol Soc. 2011 Nov;17(6):998-1005.
Cognivue, Inc.
Medical Equipment Manufacturing
Victor, New York 7,424 followers
A Path to Cognitive Health and Peace of Mind
About us
Cognivue is a risk assessment test that identifies changes in cognitive function that could be indicative of early dementia or Alzheimer's Disease. It is the world's first FDA-Cleared computerized test of cognitive function. Cognivue was designed to objectively, quantitatively and reliably identify changes in cognitive function that could be indicative of early dementia or Alzheimer's Disease. It allows clinicians the opportunity to establish a baseline cognitive score that can be monitored over time. Cognivue measures and monitors cognitive health by testing 4 key cognitive domains. This 10 minute test measures tracking movement, vision, perception and memory of letters, words, shapes and motion. Unlike paper and pencil cognitive testing, Cognivue is based on neurophysiology and psychophysical research. Upon completion of the test, Cognivue immediately creates a report with a clinical risk score of cognitive health. Using the patient's risk score, you will be able to determine the patient's risk stratification and proper course of action to improve patient care.
- Website
-
http://cognivue.com
External link for Cognivue, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Victor, New York
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
7911 Rae Blvd
Victor, New York 14564, US
Employees at Cognivue, Inc.
-
Rosemarie Paratore
Vice President, Quality at Cognivue, Inc.
-
Susan Lutz
Business Development, Market Access, Trade Distribution Relations, Population Health Analytics, Connected Health
-
Kristin Weber
Director Strategic Accounts at Cognivue, Inc.
-
Joel Raskin
Medical, Scientific and Strategic Consultant
Updates
-
That’s a wrap for the 2024 Alzheimer's Association® International Conference (AAIC). It was an exciting few days of hearing professionals speak on an assortment of important topics around the many changes happening in the dementia space. We look forward to seeing how outputs from AAIC 2024 will shape Alzheimer’s research to come. Since inception, Cognivue, Inc. has invested in developing its cognitive assessment platform to advance technologies used in screening for Alzheimer’s disease and other related dementias. Meet with us and learn more about our platform: [email protected]. #aaic24 #alzheimersdisease #alzheimers #cognitiveassessment #brainhealth #earlydetection #makingadifference #cognivue
-
-
Poster presentation happening TODAY at the Alzheimer’s Association International Conference (AAIC). Cognivue, Inc.’s poster #86341 will be on display between 7:30am-4:15pm in the Pennsylvania Convention Center – Level 200, Halls B-C. Poster: Detection of Amyloid Status and Preclinical Alzheimer’s Disease Using Cognivue Clarity®, An Adaptive Psychophysics Computerized Cognitive Battery in The Bio-Hermes Study. Data from the Bio Hermes study, sponsored by the Global Alzheimer's Platform Foundation. For more information contact us at [email protected]. #aaic24 #biomarkers #alzheimersdisease #AD #amyloid #preclinical #mildcognitiveimpairment #milddementia #dca #assessment #cognitivehealth #biohermes #earlydetection #cognivue
-
-
Meet with Cognivue, Inc. at the 2024 Alzheimer's Association® International Conference (AAIC) taking place July 28-August 1 in Philadelphia, PA. To set-up a meeting with one of our representatives, contact [email protected]. Learn more about what Cognivue’s technology can do. The Cognivue Clarity assessment offers an advanced approach to brain performance measurement that is robust, validated, flexible, and personalized. Stay tuned for our AAIC poster #86341 presentation on Monday, July 29th with research updates. #aaic24 #alzheimersdisease #alzheimers #AD #clinicaltrial #research #DCA #cognitiveassessment #cognitivehealth #earlydetection #cognivue
-
-
Imagine a world where individuals at risk of developing Alzheimer’s disease could be identified early—and treatment recommendations could be applied to slow the progression or reduce risk factors. What Does the Preclinical Phase Mean: 👉 When an individual has evidence of AD pathologic markers in the brain, such as amyloid, but they are not showing cognitive and functional problems. There are multiple clinical trials that specifically focus on this Preclinical phase of the disease, as researchers are hoping to reduce the likelihood of or slow down the progression of cognitive decline associated with Alzheimer’s disease as early and as much as possible. Alzheimer’s disease begins 20 years or more before memory loss and other symptoms develop [1], so research into identifying and treating this early phase in the continuum is of increasing importance. Based on data from the recent Bio-Hermes study, Cognivue Clarity showed that it was able to digitally detect the presence of amyloid. Research will help explore if a Digital Cognitive Assessment (DCA) tool like Cognivue Clarity can play a role in early identification of individuals in the Preclinical phase. Cognivue, Inc. will have more research updates at the upcoming Alzheimer's Association International Conference (AAIC) taking place on July 28-August 1, so be on the lookout for future posts. #earlydetection #alzheimersdisease #alzheimers #AD #preclinical #cognitivehealth #cognitivescreening #DCA #clinicaltrial #research #Cognivue Reference: [1] Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5).
-
-
Exercise Regularly (#tiptuesday)! Studies show that taking proactive steps may help reduce the risk of memory loss and other forms of cognitive decline[1]. Research supports a strong link between physical activity and brain health. It is recommended to get at least 150 minutes of moderate aerobic activity a week[2]. Any activity that gets the heart pumping counts as aerobic activity, such as walking, dancing, and biking. #modifiableriskfactor #prevention #healthandwellness #lifestyle #brainhealth #cognitivescreening #Cognivue References: 1. Dementia. (2022, September 20). Retrieved November 20, 2022, from https://bit.ly/3yQEfg8. 2. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. Washington, DC: U.S. Department of Health and Human Services; 2018.
-
-
Cognivue, Inc. celebrates as even more progress is made in the fight against Alzheimer’s disease! Yesterday’s approval by the #FDA of #Kisunla was yet another important step forward in offering new treatment options for Alzheimer’s disease when diagnosed early. This approval continues to lay the groundwork for even more research and development in this area. This step forward ties so closely to Cognivue’s mission to provide cognitive assessment tools that assist healthcare providers with early-stage detection of cognitive changes. Early detection, using an assessment tool like Cognivue Clarity, helps identify individuals who may need a full work-up as part of the diagnostic process. Early diagnosis of Alzheimer’s disease allows for new treatment recommendations, like the newly FDA approved Kisunla, that have been shown to be effective in slowing down the progression of cognitive decline in persons who are amyloid positive and in earlier phases of the Alzheimer’s disease continuum—in either mild cognitive impairment (MCI) or mild dementia phases (and may no longer be options in later phases of the continuum). #kisunla #donanemab #alzheimers #alzheimersdisease #progress #FDA #earlydetection #cognitivehealth #makingadifference #brighterfuture https://bit.ly/3W7XzPj
-
Cognivue, Inc.'s FOCUS study, just published in June 2024 in The Journal of Alzheimer’s Disease, examined the use of Cognivue Clarity® as a valid measure of cognitive performance in a diverse population. Link: https://bit.ly/3RSGjLv Main Takeaways: 👍 Based on a diverse sample that reflects many of the demographic characteristics of the US population, study data suggest Cognivue Clarity offers a quick, valid, and reliable measure of cognitive functions with limited practice effects when compared to a gold standard neuropsychological testing instrument. 👍 Cognivue Clarity can be used to effectively evaluate cognitive performance and screen individuals for cognitive impairment over time and can improve detection of cognitive changes, including MCI, in community settings, which is important in early detection and screening for cognitive changes across diverse populations. #research #diversity #cognitivehealth #cognitivescreening #cognitivechanges #cognivue Reference: Galvin JE, Chang LC, Estes PW, et al. Cognitive Assessment with Cognivue Clarity®: Psychometric Properties and Normative Ranges in a Diverse Population. Journal of Alzheimer’s Disease. 2024 Jun 14. doi: 10.3233/JAD 240331. Online ahead of print.
Cognitive Assessment with Cognivue Clarity®: Psychometric Properties and Normative Ranges in a Diverse Population - PubMed
pubmed.ncbi.nlm.nih.gov
-
Research has shown that early detection and people taking action when it matters most can prevent, delay, or slow the onset of cognitive decline [1]. The Lancet Commission reported that 40% of the risk factors for dementia can be modified with lifestyle changes [2]. And now we know that in cases of cognitive decline due to Alzheimer’s disease, the disease begins 20 years or more before memory loss and other symptoms develop [3]. There are lots of evidence-based recommendations out there to help individuals proactively manage lifestyle-related risk factors and medical conditions that may affect cognition (and conversely, cognition affects how risk factors and medical conditions are managed). As it's Alzheimer’s and Brain Awareness Month, we are reminded of how important it is for individuals to adopt a combination of key healthy lifestyle habits, develop good awareness of overall wellness, and optimize their cognition by taking early and proactive steps that may help reduce the risk of memory loss and other forms of cognitive decline [4]. Using cognitive assessment tools like Cognivue Clarity and Cognivue Thrive for early detection of cognitive changes allows individuals to address modifiable risk factors sooner, potentially changing the course of cognitive decline. #AlzheimersAndBrainAwarenessMonth #EndAlz #AlzheimersAwareness #GoPurple #earlydetectionmatters #cognitivescreening #brainhealth #modifiableriskfactors #cognivue References: [1] Reducing Risk of Alzheimer’s Disease. (2022, September 13). Centers for Disease Control and Prevention. https://bit.ly/4biZ1Ta [2] Livingston G et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020 Aug 8;396(10248):413-44 [3] Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5) [4] Dementia. (2022, September 20). Retrieved November 20, 2022, from https://bit.ly/4bfwP3v
-
-
The FDA clearance of Leqembi and the recent endorsement of donanemab by an independent panel of advisors to the FDA point to the importance of early detection of cognitive changes as well as amyloid status. These new treatment options have been shown to be effective in slowing the progression of cognitive decline in persons who are amyloid positive and in earlier phases of the disease continuum—in either mild cognitive impairment (MCI) or mild dementia phases [1,2]. Mild Cognitive Impairment (MCI): - Amyloid-positive individuals who have mild yet subtle cognitive problems but without noticeable changes in their ability to perform their usual basic or instrumental activities of daily living. - Note: While every Alzheimer’s disease patient goes through this phase, not everyone with MCI progresses further [3]. Some either do not have further decline or show improvement in their cognition [4]. Dementia Due to AD - Mild: - Individuals who experiences cognitive problems that have become more noticeable over time and beginning to affect their ability to maintain their performance in day-to-day living (i.e. being able to manage their finances and medications on their own). They may begin to struggle and need help with certain daily living activities in order to maintain their usual level of functioning. Some cognitive changes are normal as we age, and all of us experience them, but not everyone has the more serious cognitive decline that come with Alzheimer’s disease or other dementias. Early detection of cognitive changes, using an assessment tool like Cognivue Clarity, helps identify individuals who may need a full work-up as part of the diagnostic process. Early diagnosis allows for treatment recommendations that could potentially change the course of cognitive decline—this may include one of the new drug(s) to slow the progression of early Alzheimer’s disease, and/or identification and reduction of risk factors. These same treatment recommendations may no longer be options in later phases of the Alzheimer’s disease continuum. With June being Alzheimer’s and Brain Awareness month, we want to raise awareness of the growing importance of early detection, especially as new drug(s) come to market requiring an early-stage diagnosis. #AlzheimersAndBrainAwarenessMonth #endalz #AlzheimersAwareness #thelongestday #mild #alzheimers #mildcognitiveimpairment #brainhealth #cognitivehealth #earlydetection #cognitivescreening Cognivue, Inc. Alzheimer's Association® Eisai U.S. Alzheimer’s Disease and Brain Health Eli Lilly and Company References: [1] https://bit.ly/4cpOKp7 [2] https://bit.ly/3zjRHt2 [3] Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5). [4] Canevelli M, et al. Spontaneous reversion of mild cognitive impairment to normal cognition...
-